The findings, first reported at the American Academy of Pain Medicine’s annual meeting, suggest that a unique microglial target can effectively treat the disorder, according to lead investigator Jarred Younger, PhD.
Despite the study’s promising data, the low-dose amount of naltrexone used on participants is not yet commercially available and must be compounded manually for patients.
Related Articles on Pain Management:
Florida Pain Network Adds Orlando Clinics to Expanded Database
Study: Risk of Perioperative Infection Lower in Patients With Chronic Opioid Consumption
Ameritox Supports New Recommendations for Long-Term Opioid Therapy
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
